US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

58.76

+1.392.43%

Post-market: 58.800.0430+0.07%19:30 EDT

Volume:17.38K

Turnover:1.02M

Market Cap:284.38M

PE:19.22

High:59.14

Open:57.66

Low:57.66

Close:57.37

52wk High:64.10

52wk Low:44.47

Shares:4.84M

Float Shares:4.84M

Volume Ratio:0.51

T/O Rate:0.36%

Dividend:1.53

Dividend Rate:2.60%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Revolution Medicines (RVMD) Starts Phase 3 RASolute 309, Is It Still A Bargain?

Simply Wall St.

Axsome Therapeutics (AXSM) Gets a Buy from Bank of America Securities

Contec Medical Systems Secures Medical Device Registration Certificate for Color Doppler Ultrasound Diagnostic System

Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion

Guardant Health Wins EU CE Mark for Guardant360 CDx as Camizestrant Companion Diagnostic in ER-Positive Breast Cancer

Guardant Health Announces Approval in Europe of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Er-Positive Breast Cancer

THOMSON REUTERS

Guardant Health to Report Q3 2026 Financial Results After Market Close, Host Conference Call

RBC would be buyers of Revolution Medicines after FDA docs ‘overreaction’

Revolution Medicines selloff ‘overdone and misguided,’ says TD Cowen

Revolution Medicines Falls on Pancreatic Cancer Drug Data Concerns

Axsome Therapeutics on Pace for Longest Losing Streak Since December 2018

Revolution trading down after daraxonrasib review docs, says Stifel

Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting

Axsome Therapeutics, Inc. : RBC Cuts Target Price to $295 from $297

THOMSON REUTERS

Shandong Oriental Ocean's Subsidiary Secures Medical Device Registration Certificate for Water-Soluble Vitamin Assay Kit

Beijing Strong Biotechnologies Secures Medical Device Registration Certificates for Five Products

Will Phase 3 Trial Start Change Revolution Medicines (RVMD) Narrative

Simply Wall St.

Centinel Spine Reports 42% Revenue Surge and Return to Profit as It Pursues U.S. IPO, Testing Valuations for Innovative Medical Devices

Newron presses on with ENIGMA-TRS program as FDA clinical hold prompts safety review

Guardant Health is Maintained at Overweight by Barclays

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/PTH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":58.757,"timestamp":1791576000000,"preClose":57.3658,"halted":0,"volume":17383,"hourTrading":{"tag":"盘后","latestPrice":58.8,"preClose":58.757,"latestTime":"19:30 EDT","volume":6,"amount":352.2346,"timestamp":1791588604239,"change":0.043,"changeRate":0.000732,"amplitude":0},"delay":0,"changeRate":0.024251383228334613,"floatShares":4840000,"shares":4840000,"eps":3.057033,"marketStatus":"Market Closed","change":1.3912,"latestTime":"10-09 16:00:00 EDT","open":57.66,"high":59.1447,"low":57.66,"amount":1021175.720865,"amplitude":0.025881,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":57.3658,"sharesOutstanding":2480000,"nav":57.33757,"aum":287288216.63,"dividendRate":0.02597,"bidAskSpread":0.001697,"preHourTrading":{"tag":"盘前","latestPrice":57.37,"preClose":57.3658,"latestTime":"07:00 EDT","volume":1,"amount":57.37,"timestamp":1791543606921,"change":0.0042,"changeRate":0.000073,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":58.8,"preClose":58.757,"latestTime":"19:30 EDT","volume":6,"amount":352.2346,"timestamp":1791588604239,"change":0.043,"changeRate":0.000732,"amplitude":0},"volumeRatio":0.5106189207267566,"impliedVol":0.2074,"impliedVolPercentile":0.9442},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4840000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5106189207267566,"shares":4840000,"dividePrice":1.5259,"high":59.1447,"amplitude":0.025881,"preClose":57.3658,"low":57.66,"week52Low":44.47,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":58.757,"eps":3.057033,"divideRate":0.02597,"volume":17383,"delay":0,"ttmEps":3.057033,"open":57.66,"prevYearClose":49.701,"prevWeekClose":60.2082,"prevMonthClose":60.76,"prevQuarterClose":60.76,"fiveDayClose":60.2082,"twentyDayClose":60.7692,"sixtyDayClose":58.2191},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674995828","title":"Revolution Medicines (RVMD) Starts Phase 3 RASolute 309, Is It Still A Bargain?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674995828","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674995828?lang=en_us&edition=fundamental","pubTime":"2026-10-10 14:29","pubTimestamp":1791613755,"startTime":"0","endTime":"0","summary":"Why the RASolute 309 trial matters for Revolution Medicines\nRevolution Medicines (RVMD) has started treating patients in its RASolute 309 Phase 3 trial, testing RASONQUE with zoldonrasib as a first-line option for metastatic RAS G12D pancreatic cancer.\nThe study compares this combination against standard chemotherapy gemcitabine and nab paclitaxel, with progression free survival and overall survival as dual primary endpoints that investors will watch closely.\nRevolution Medicines sits at...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-starts-phase-3-rasolute-309-is-it","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-starts-phase-3-rasolute-309-is-it","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONX","IE0009354923.USD","LU1978683503.SGD","LU0320765992.SGD","BK4512","LU1548497426.USD","BK4141","ONG","LU2360107325.USD","LU0348723411.USD","LU1720051017.SGD","IE00BJJMRZ35.SGD","LU1861219969.SGD","IE00BD6J9T35.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","CANC","LU1861220033.SGD","LU0724618433.USD","LU0124384867.USD","LU1861215975.USD","LU0109394709.USD","IDNA","PTH","IE0002141913.USD","IE00B2B36J28.USD","LU1854104046.USD","LU2357305700.SGD","LU1854103824.USD","BK4139","LU1720051108.HKD","LU2298322129.HKD","BK4605","IE00BZ199S13.USD","IE00BJT1NW94.SGD","LU1861214812.USD","RVMD","BK4585","ON","LU0889565916.HKD","IE00BFMHRM44.USD","BK4588","BBH","IE0009355771.USD","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674852947","title":"Axsome Therapeutics (AXSM) Gets a Buy from Bank of America Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2674852947","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674852947?lang=en_us&edition=fundamental","pubTime":"2026-10-09 21:16","pubTimestamp":1791551784,"startTime":"0","endTime":"0","summary":"In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Axsome Therapeutics, with a price target of $...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/axsome-therapeutics-axsm-gets-a-buy-from-bank-of-america-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/axsome-therapeutics-axsm-gets-a-buy-from-bank-of-america-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UYG","LU0130518102.USD","BK4588","IYG","IE00BBT3K403.USD","IE00BZ1G4Q59.USD","PGF","BAC","LU2129689605.HKD","LU1291159041.SGD","IYF","LU0971096721.USD","LU1162221912.USD","FTXO","LU1496350171.SGD","LU0098860793.USD","IE00BKVL7J92.USD","LU0306807586.USD","LU0321505439.SGD","BK4504","IE00B19Z3581.USD","BK4585","LU1668664300.SGD","XLF","LU0868494617.USD","AXSM","LU1791807156.HKD","FNCL","LU1989771016.USD","LU0320765646.SGD","LU1894683264.USD","VFH","LU0052756011.USD","LU0170899867.USD","LU0980610538.SGD","IE00B19Z3B42.SGD","LU0234572021.USD","LU1035773651.USD","LU0256863811.USD","LU2265009873.SGD","LU0306806265.USD","KBWB","LU0648001328.SGD","TFNS","BK4534","PTH","LU1363072403.SGD","IE0002270589.USD","LU2129689431.USD","LU0787776722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119313877","title":"Contec Medical Systems Secures Medical Device Registration Certificate for Color Doppler Ultrasound Diagnostic System","url":"https://stock-news.laohu8.com/highlight/detail?id=1119313877","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119313877?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:00","pubTimestamp":1791543614,"startTime":"0","endTime":"0","summary":"Contec Medical Systems Co.,Ltd. (300869.SZ) has announced that the company recently obtained a Medical Device Registration Certificate of the People's Republic of China issued by the Hebei Provincial...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RSPH","BK0251","BK1574","MEDX","LNGR","MDEV","159883","09996","LGHT","BK1583","HART","PTH","IEIH","300869","AGNG","BK1100","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674000684","title":"Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000684","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000684?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:15","pubTimestamp":1791490537,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that Guardant360 CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a comp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-europe-approval-of-guardnat360-cdx-as-etcamaha-companion-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-europe-approval-of-guardnat360-cdx-as-etcamaha-companion-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","LU0889565916.HKD","LU0109394709.USD","GNOM","GNMX","EKG","BK4551","LFSC","BK4535","FFOX","GH","HELX","BK4588","PTH","LU0320765992.SGD","GDOC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674000800","title":"Guardant Health Wins EU CE Mark for Guardant360 CDx as Camizestrant Companion Diagnostic in ER-Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000800","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000800?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:12","pubTimestamp":1791490344,"startTime":"0","endTime":"0","summary":"Guardant Health wins EU CE mark for Guardant360 CDx as camizestrant companion diagnostic in ER-positive breast cancerGuardant Health secured EU CE-marking for Guardant360 CDx as a companion diagnostic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL7WpmQr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","GNMX","GNOM","PTH","BK4585","LFSC","BK4588","BK4551","BK4196","EKG","GDOC","FFOX","BK4535","HELX","LU0109394709.USD","LU0889565916.HKD","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674802000","title":"Guardant Health Announces Approval in Europe of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Er-Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674802000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674802000?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:12","pubTimestamp":1791490320,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nTUA8LV3XK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2125909247.SGD","HELX","LU0029864427.USD","LU0823399737.USD","LU1261432733.SGD","LU1481599808.USD","LU1989772923.USD","LU0827474353.SGD","AZN.UK","LU0784383803.USD","LU1153584641.USD","LU0345777147.USD","LU0058720904.USD","LU2023251221.USD","LU0757432116.USD","LU1267930813.SGD","LU1863844749.USD","LU0661504455.SGD","GNMX","LU0972486137.USD","GDOC","LU1153585028.USD","PTH","EKG","LU0823416689.USD","GNOM","GH","LU2237443622.USD","LU0526926950.USD","LU1015430645.USD","IE00B3T34201.USD","LU1057294990.SGD","LU0949170426.SGD","LU2539964713.USD","03165","LU1323610961.USD","FFOX","LU0011850046.USD","LU0997586515.USD","LU2293690249.USD","LU1496350171.SGD","LU0345777659.USD","IE00BJT1NW94.SGD","LFSC","LU0882574055.USD","LU1923622614.USD","LU0960981461.USD","LU0949170772.SGD","LU0211326755.USD","LU0784385840.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674007701","title":"Guardant Health to Report Q3 2026 Financial Results After Market Close, Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2674007701","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674007701?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:05","pubTimestamp":1791489926,"startTime":"0","endTime":"0","summary":"Guardant Health to report Q3 2026 financial results after market close, host conference callGuardant Health schedules third-quarter 2026 results release for Nov. 5, 2026, following the market close.Ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDLWjfQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNMX","BK4588","GDOC","BK4551","EKG","FFOX","GH","LU0889565916.HKD","BK4585","GNOM","LFSC","BK4196","HELX","PTH","LU0320765992.SGD","BK4535","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674074190","title":"RBC would be buyers of Revolution Medicines after FDA docs ‘overreaction’","url":"https://stock-news.laohu8.com/highlight/detail?id=2674074190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674074190?lang=en_us&edition=fundamental","pubTime":"2026-10-09 03:45","pubTimestamp":1791488724,"startTime":"0","endTime":"0","summary":"RBC Capital notes Revolution Medicines (RVMD) looks to be down in response to yesterday’s disclosure of FDA’s Rasonque review documents, particular...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-would-be-buyers-of-revolution-medicines-after-fda-docs-overreaction-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-would-be-buyers-of-revolution-medicines-after-fda-docs-overreaction-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IE00B2B36J28.USD","LU0889565916.HKD","GSIB","LABU","BK4588","BBH","LU0109394709.USD","BK4207","LU0708994859.HKD","BK4585","LU0128525929.USD","LU1267930573.SGD","LU0310800379.SGD","CANC","PTH","IDNA","IE0009354923.USD","IE0009355771.USD","IE0002141913.USD","RVMD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0029864427.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674077820","title":"Revolution Medicines selloff ‘overdone and misguided,’ says TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2674077820","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674077820?lang=en_us&edition=fundamental","pubTime":"2026-10-09 03:40","pubTimestamp":1791488425,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Revolution Medicines (RVMD), saying Thursday’s selloff on Rasonque’s reported efficacy ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-selloff-overdone-and-misguided-says-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-selloff-overdone-and-misguided-says-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","BBH","IE0009355771.USD","COWN","IDNA","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00B2B36J28.USD","IE0009354923.USD","IE00BJT1NW94.SGD","RVMD","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4127","CANC","BK4139","PTH","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674004785","title":"Revolution Medicines Falls on Pancreatic Cancer Drug Data Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2674004785","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674004785?lang=en_us&edition=fundamental","pubTime":"2026-10-09 02:17","pubTimestamp":1791483427,"startTime":"0","endTime":"0","summary":"BUZZ-Revolution Medicines falls on pancreatic cancer drug data concerns** Shares of Revolution MedicinesRVMD.Odown 8.1% at $185.91 in afternoon trading** RBC Capital Markets says stock looks to be dow","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nL4N45U1II:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B4R5TH58.HKD","BK4139","PTH","LU0889565916.HKD","RVMD","LU0109394709.USD","IE0009354923.USD","BBH","CANC","IE0002141913.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0320765992.SGD","IE00BJJMRZ35.SGD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674992009","title":"Axsome Therapeutics on Pace for Longest Losing Streak Since December 2018","url":"https://stock-news.laohu8.com/highlight/detail?id=2674992009","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674992009?lang=en_us&edition=fundamental","pubTime":"2026-10-09 00:15","pubTimestamp":1791476100,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc.  is currently at $166.21, down $6.76 or 3.91%--Would be lowest close since March 30, 2026, when it closed at $160.50--On pace for largest percent decrease since Sept. 29, 2026, when it fell 4%--Currently down 14 of the past 15 days--Currently down 10 consecutive days; down 15.21% over this period--Longest losing streak since Dec. 27, 2018, when it fell for 11 straight trading days--Worst 10-day stretch since the 10 days ending April 11, 2025, when it fell 17.27%--Down 9.86% month-to-date--Down 9% year-to-date; on pace for worst year since 2021, when it fell 53.63%--Down 34.86% from its all-time closing high of $255.17 on June 12, 2026--Up 35.66% from 52 weeks ago , when it closed at $122.52--Down 34.86% from its 52-week closing high of $255.17 on June 12, 2026--Up 37.19% from its 52-week closing low of $121.15 on Oct. 13, 2025--Traded as low as $166.21; lowest intraday level since April 7, 2026, when it hit $165.17--Down 3.91% at today's intraday lowAll data a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4505","LU2324357040.USD","BK4585","PTH","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674091230","title":"Revolution trading down after daraxonrasib review docs, says Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2674091230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674091230?lang=en_us&edition=fundamental","pubTime":"2026-10-09 00:05","pubTimestamp":1791475557,"startTime":"0","endTime":"0","summary":"Stifel says shares of Revolution Medicines (RVMD) are lower after the FDA posted multidisciplinary review documents for daraxonrasib with additiona...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-trading-down-after-daraxonrasib-review-docs-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-trading-down-after-daraxonrasib-review-docs-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B4R5TH58.HKD","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","BK4585","IE0009355771.USD","BK4139","IE0009354923.USD","PTH","RVMD","IE00BFTCPJ56.SGD","IDNA","BBH","BK4588","IE00B2B36J28.USD","CANC","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673072575","title":"Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2673072575","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673072575?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:00","pubTimestamp":1791460800,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Oct.  08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional presen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/08/3377187/0/en/entera-bio-announces-additional-presentation-of-eb613-phase-3-study-design-at-the-asbmr-2026-annual-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENTX","BK4139","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673526075","title":"Axsome Therapeutics, Inc. : RBC Cuts Target Price to $295 from $297","url":"https://stock-news.laohu8.com/highlight/detail?id=2673526075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673526075?lang=en_us&edition=fundamental","pubTime":"2026-10-08 18:10","pubTimestamp":1791454206,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45U116:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","LU2324357040.USD","BK4585","BK4007","AXSM","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137044188","title":"Shandong Oriental Ocean's Subsidiary Secures Medical Device Registration Certificate for Water-Soluble Vitamin Assay Kit","url":"https://stock-news.laohu8.com/highlight/detail?id=1137044188","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137044188?lang=en_us&edition=fundamental","pubTime":"2026-10-08 16:48","pubTimestamp":1791449307,"startTime":"0","endTime":"0","summary":"Shandong Oriental Ocean Sci-Tech Co.,Ltd. (002086.SZ) has announced that its subsidiary, Mass Spectrometry Biotechnology Co., Ltd., has received registration approval from the Shandong Provincial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RSPH","LNGR","LGHT","BK1100","MEDX","BK0213","MDEV","HART","09996","BK1574","BK0046","PTH","GDOC","BK1583","159883","IEIH","002086","BK0092","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175454812","title":"Beijing Strong Biotechnologies Secures Medical Device Registration Certificates for Five Products","url":"https://stock-news.laohu8.com/highlight/detail?id=1175454812","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175454812?lang=en_us&edition=fundamental","pubTime":"2026-10-08 16:27","pubTimestamp":1791448021,"startTime":"0","endTime":"0","summary":"Beijing Strong Biotechnologies, Inc. (300406.SZ) has announced that the company and its wholly-owned subsidiary, Beijing Meichuang Xinyue Medical Devices Co., Ltd., recently received Medical Device...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RSPH","300406","AGNG","MEDX","BK0012","BK0028","09996","159883","BK0077","BK1583","GDOC","LGHT","LNGR","BK0046","BK1100","BK1574","HART","BK0239","PTH","IEIH","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673017021","title":"Will Phase 3 Trial Start Change Revolution Medicines (RVMD) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2673017021","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673017021?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:26","pubTimestamp":1791444398,"startTime":"0","endTime":"0","summary":"Revolution Medicines has already started treating patients in RASolute 309, a global Phase 3 trial testing RASONQUE plus zoldonrasib as first line therapy against standard gemcitabine and nab paclitaxel in metastatic RAS G12D pancreatic cancer, with progression free and overall survival as dual primary endpoints.\nThe study targets RAS G12D, the most prevalent RAS mutation across cancers, where roughly 61,000 new U.S. patients each year currently have no approved targeted therapy. This puts...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/will-phase-3-trial-start-change-revolution-medicines-rvmd-na","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/will-phase-3-trial-start-change-revolution-medicines-rvmd-na","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1854103824.USD","PTH","LU1978683503.SGD","LU1861220033.SGD","LU2298322129.HKD","BK4141","LU1861215975.USD","BK4605","CANC","IE00BD6J9T35.USD","IE00BFMHRM44.USD","IE0009355771.USD","LU1720051017.SGD","LU0124384867.USD","LU1548497426.USD","IE0009354923.USD","LU2357305700.SGD","LU1720051108.HKD","IE00BJT1NW94.SGD","LU1861219969.SGD","IE00BJJMRZ35.SGD","IE00BZ199S13.USD","LU0109394709.USD","BK4139","BK4585","LU0320765992.SGD","LU1983260115.SGD","IDNA","LU0889565916.HKD","IE00B2B36J28.USD","RVMD","LU0724618433.USD","IE00BFTCPJ56.SGD","LU2360107325.USD","LU1854104046.USD","IE00B4R5TH58.HKD","LU1861214812.USD","ON","BK4588","ONG","BK4512","ONX","LU0348723411.USD","BBH","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113468304","title":"Centinel Spine Reports 42% Revenue Surge and Return to Profit as It Pursues U.S. IPO, Testing Valuations for Innovative Medical Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1113468304","media":"Stock News","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113468304?lang=en_us&edition=fundamental","pubTime":"2026-10-08 14:58","pubTimestamp":1791442703,"startTime":"0","endTime":"0","summary":"Centinel Spine, a well-known American medical device manufacturer, disclosed in its U.S. initial public offering filing on Wednesday local time that its first-half revenue surged 42%. The IPO...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FRHC","BK1583","REDS","KCE","GDOC","RSPH","MEDX","LGHT","LNGR","BK1574","PTH","BK1100","09996","159883","MDEV","BK4127","AGNG","HART","IPOS","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673023384","title":"Newron presses on with ENIGMA-TRS program as FDA clinical hold prompts safety review","url":"https://stock-news.laohu8.com/highlight/detail?id=2673023384","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673023384?lang=en_us&edition=fundamental","pubTime":"2026-10-08 13:32","pubTimestamp":1791437568,"startTime":"0","endTime":"0","summary":"An announcement from Newron Pharmaceuticals SpA ( ($CH:NWRN) ) is now available. Newron Pharmaceuticals has received a formal notification from the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/newron-presses-on-with-enigma-trs-program-as-fda-clinical-hold-prompts-safety-review?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/newron-presses-on-with-enigma-trs-program-as-fda-clinical-hold-prompts-safety-review?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYNB","BK4588","MEDX","BK4585","PTH","IBB","BBC","BIS","IBBQ","PILL","PSCH","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673162670","title":"Guardant Health is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673162670","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673162670?lang=en_us&edition=fundamental","pubTime":"2026-10-07 22:43","pubTimestamp":1791384180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4196","LU0889565916.HKD","FFOX","LU0320765992.SGD","LFSC","BK4551","PTH","BK4585","GDOC","GH","EKG","HELX","GNMX","BK4535","LU0109394709.USD","GNOM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}